PTC Therapeutics’ board authorized a share repurchase program allowing the company to buy back up to $500 million of its common stock. The authorization gives management flexibility to make purchases over time; it does not require PTC to spend the full amount or set a timetable for purchases.
Chief Executive Matthew B. Klein said the program reflects confidence in PTC’s growth prospects and the view that its shares represent an attractive investment, while preserving flexibility to fund existing programs and pursue potential business-development deals.
Key details
- Size: PTC may repurchase up to $500 million of its outstanding common stock.
- Timing and pace: Management will decide whether and when to make purchases, depending on market conditions. No minimum purchase amount or completion date was specified.
- Methods: Purchases may take place in the open market, including through preset trading plans, or through privately negotiated deals, accelerated repurchases and other permitted transactions.
- Capital-allocation rationale: Klein said PTC intends to maintain financial flexibility to support its existing programs and pursue potential value-creating business-development transactions alongside the buyback.
- Reporting: PTC said information on any repurchases will appear in its subsequent quarterly and annual reports.
Plain-English implications
The authorization creates the option for PTC to return capital to shareholders through stock buybacks, but does not establish how much cash the company will actually use. Any shares repurchased would reduce the number of outstanding shares; the scale and timing of that effect depend on purchases made under the program.